G. Bradley Cole
About G. Bradley Cole
Independent director of Kiniksa Pharmaceuticals International, plc since July 2020; age 69; veteran finance executive with >25 years in life sciences. He holds a B.S. in Business from Biola University and an M.B.A. from San Jose State University . He is designated an “audit committee financial expert” by Kiniksa’s Board and is independent under Nasdaq rules .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Genomic Health, Inc. | CFO; COO; Secretary | CFO: Jul 2004–Jan 2011 and Jul 2014–Nov 2019; COO: Jan 2009–Mar 2018; Secretary: Feb 2005–Jul 2012 | Led finance and operations; helped manage sale to Exact Sciences; extensive operating experience |
| Exact Sciences Corp. | Executive Advisor; GM, Precision Oncology | Nov 2019–Apr 2020 (GM); Apr 2020–Sep 2020 (Advisor) | Post‑acquisition integration and leadership in precision oncology |
| Guidant Corporation / Endovascular Technologies, Inc. | VP Finance & BD (Guidant Endovascular); CFO (Endovascular Technologies) | Dec 1997–May 2004 (Guidant); Jan 2001–May 2004 (Endovascular) | Finance leadership in medical devices; acquisition integration experience |
| Applied Biosystems Incorporated | VP Finance & CFO | Prior to Guidant (dates not separately disclosed) | Life sciences systems finance leadership |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Castle Biosciences, Inc. | Director | Current | Skin cancer diagnostics board service; governance oversight |
| Genomic Life, Inc. | Chief Financial Officer; Director | CFO since Feb 2022; board service current | Private company; financial leadership |
| Biola University | Vice Chairman, Board of Trustees | Current | Academic governance leadership |
Board Governance
- Independence: Kiniksa’s board has 9 of 10 independent directors; Cole is independent under Nasdaq rules .
- Committees: Member, Audit Committee; Audit met 4 times in 2024; Board determined Cole is an “audit committee financial expert” .
- Attendance: Four board meetings in 2024; each director attended at least 75% of board and committee meetings .
- Lead Independent Director: Felix J. Baker (separate from CEO/Chair); regular executive sessions of independent directors .
Fixed Compensation
| Component | 2024 Amount (USD) | Notes |
|---|---|---|
| Board annual cash retainer | $40,000 | Standard director retainer |
| Audit Committee member fee | $9,000 | Member fee (non‑chair) |
| Total cash fees (Cole) | $49,000 | Reported in 2024 Director Compensation Table |
Performance Compensation
Non‑employee director pay has no performance-based incentive components; equity awards are time‑vested options and RSUs .
| Equity Component | 2024 Grant Value (USD) | Vesting Structure |
|---|---|---|
| Stock options (Cole) | $225,053 | Annual director options vest in 12 equal monthly installments post‑grant |
| RSUs (Cole) | $62,540 | Annual director RSUs vest in full by the next annual meeting or 1 year from grant; initial awards vest over 3 years |
Other Directorships & Interlocks
- Current public board: Castle Biosciences, Inc. (diagnostics) .
- Notable interlock: Kimberly J. Popovits (KNSA director) previously served as Genomic Health’s Chairman/CEO; Cole held CFO/COO roles there—shared prior affiliation, but no related‑party transactions disclosed for Cole .
Expertise & Qualifications
- Audit and finance leadership across diagnostics and medical devices; CFO/COO track record at Genomic Health; finance and BD at Guidant/Endovascular .
- Designated audit committee financial expert by the Board .
- Prohibited hedging/pledging policy applies company‑wide to insiders .
Equity Ownership
| Metric | Amount | Details |
|---|---|---|
| Beneficial ownership (Class A) | 159,024 shares | Includes 9,373 direct and 149,651 shares acquirable within 60 days via options/RSUs; <1% of Class A outstanding |
| Options held (Dec 31, 2024) | 146,478 | Aggregate option awards outstanding |
| RSUs held (Dec 31, 2024) | 3,173 | Aggregate RSUs outstanding |
Insider Trades (Form 4)
| Date (Filing/Report) | Transaction | Shares | Source |
|---|---|---|---|
| 2024-06-07 (reporting period around 2024-06-05) | Sale | 4,373 | RedChip transaction log for KNSA insiders |
| 2025-06-05 (period of report 2025-06-03) | Form 4 filed (details in EDGAR) | n/a | SEC EDGAR index for Cole (CIK 0001337798) filing on 2025-06-05 |
| 2025-06-05 | Form 4 PDF (company site) | n/a | Kiniksa investors portal Form 4 document |
Note: Company insider policy prohibits hedging and pledging; trades often occur under 10b5‑1 plans .
Governance Assessment
- Board effectiveness: Strong independence (9/10), separate Lead Independent Director, and 100% independent committees; Cole adds deep CFO/COO expertise and serves as an audit committee financial expert—positive for investor confidence .
- Engagement: Attendance met company’s threshold; audit committee active (4 meetings) .
- Alignment: Director equity grants and ongoing option/RSU holdings provide exposure to long‑term equity value; however, director pay is not performance‑conditioned (typical for non‑employee directors) .
- Conflicts/related parties: No related‑party transactions disclosed for Cole; one fellow director (Dr. Levy) had separate consulting arrangements disclosed—Audit Committee oversees related‑party reviews under formal policy .
- Policies and controls: Prohibition on hedging/pledging and clawback policy for executives; strong governance framework with regular executive sessions and board/committee self‑evaluations .
- RED FLAGS: None disclosed for Cole (no pledging/hedging, no related‑party transactions, no attendance issues) .